Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Zhongguo Fei Ai Za Zhi
2017 Feb 20;202:124-129. doi: 10.3779/j.issn.1009-3419.2017.02.07.
Show Gene links
Show Anatomy links
[Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients].
Gao Q
,
Jiang X
,
Huang C
.
Abstract
Lung cancer is the leading cause of cancer death in China. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, with the majority of the cases diagnosed at the advanced stage. Molecular targeted therapy is becoming the focus attention for advanced NSCLC. Echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene (EML4-ALK) is among the most common molecular targets of NSCLC; its specific small-molecule tyrosine kinase inhibitors (TKIs) are approved for use in advanced NSCLC cases of ALK-positive. However, the influence of EML4-ALK fusion gene on the outcome of early-stage NSCLC cases and the necessity of application of TKIs for early-stage ALK-positive NSCLC patients are still uncertain. In this paper, we summarized the progression of testing methods for ALK-positive NSCLC patients as well as clinicopathological implication, outcome, and necessity of application of TKIs for early-stage ALK-positive NSCLC patients.
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014, Pubmed
Blackhall,
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.
2014,
Pubmed
Chen,
Cancer statistics in China, 2015.
2016,
Pubmed
Choi,
A novel fusion of TPR and ALK in lung adenocarcinoma.
2014,
Pubmed
,
Echinobase
Choi,
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
2008,
Pubmed
Ettinger,
Non-small cell lung cancer clinical practice guidelines in oncology.
2006,
Pubmed
Friboulet,
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
2014,
Pubmed
Hong,
HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma.
2014,
Pubmed
,
Echinobase
Kim,
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
2012,
Pubmed
Kim,
SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.
2016,
Pubmed
Kim,
Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
2014,
Pubmed
Kodama,
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
2014,
Pubmed
Koivunen,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
2008,
Pubmed
Lee,
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
2012,
Pubmed
Liu,
[Value of Immunohistochemical Methods in Detecting EML4-ALK Fusion Mutations: A Meta-analysis].
2016,
Pubmed
Ohba,
Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
2016,
Pubmed
Ou,
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
2014,
Pubmed
Paik,
Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.
2012,
Pubmed
Pyo,
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
2016,
Pubmed
Rikova,
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.
2007,
Pubmed
Rodig,
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
2009,
Pubmed
Selinger,
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.
2013,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
Shen,
Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
2015,
Pubmed
Socinski,
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
2013,
Pubmed
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Solomon,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
2014,
Pubmed
Takeda,
Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
2012,
Pubmed
Takeuchi,
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
2009,
Pubmed
Tantraworasin,
Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non- small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies.
2014,
Pubmed
Togashi,
KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.
2012,
Pubmed
Viala,
[Second generation ALK inhibitors in non-small cell lung cancer: systemic review].
2015,
Pubmed
von Laffert,
Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.
2014,
Pubmed
Warth,
EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.
2014,
Pubmed
Wu,
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
2012,
Pubmed
,
Echinobase
Wynes,
An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators.
2014,
Pubmed
Yan,
Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer.
2014,
Pubmed
Yang,
Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
2012,
Pubmed
Ying,
Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
2013,
Pubmed
Zhang,
[Anaplastic lymphoma kinase fusion gene expression, clinical pathological characteristics and prognosis in 95 Chinese patients with non-small cell lung cancer].
2014,
Pubmed
Zhao,
Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis.
2015,
Pubmed
,
Echinobase
Zheng,
National estimates of cancer prevalence in China, 2011.
2016,
Pubmed
Zhou,
Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening.
2014,
Pubmed
Zhou,
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages.
2013,
Pubmed